← Home / BIOAGE LABS, INC. (BIOA)
Stock Analysis
BIOAGE LABS, INC. (BIOA)
BIOA
BIOA · Market data
9.04 -63.62%
Track BIOA in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when BIOA price is:
52W Range Position
23%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 16:45 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Strong / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
16.52
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
8
●
Financial Results
HIGH
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
(NASDAQ: BIOA) ("BioAge” or, "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today provided business updates and reported its first quarter 2026 financial results.
8-K Filing • SEC EDGAR
What's Driving BIOA?
📈 Technical recovery is improving
Momentum is Neutral. Watch 16.52 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
24.8
Price Chart
BIOA — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$401.3M
Company size
EV
$167.7M
Debt-adjusted value
P/E
-4.5
Not meaningful
P/S
38.9
Very high
P/B
1.1
Low book multiple
EV/Sales
16.3
Premium
EV/EBIT
-1.6
Not meaningful
P/FCF
-4.5
Not meaningful
FCF Yield
-22.19%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
2.77M
↗ Strong
📈 Net Income
-22.25M
↘ Negative
🧮 EPS (Basic)
-0.52
↘ Negative
BIOAGE LABS, INC.
Related Opportunities